Target of prophylaxis in severe haemophilia: More than factor levels

Blood Transfusion

Volumn 11, Issue 3, 2013, Pages 327-329

  Coppola, Antonio ^a   Franchini, Massimo ^b  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

EDITORIAL; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PHENOTYPE; QUALITY OF LIFE; WORLD HEALTH ORGANIZATION; FEMALE; HEMORRHAGE; MALE;

FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; QUALITY OF LIFE;

EID: 84882423386     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0244-12     Document Type: Editorial

References (28)

1. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-42.
2. Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
3. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38: 79-94.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
5. Gringeri A, Lundin B, von Mackensen S et al. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9: 700-10.
6. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
7. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
8. Srivastava A, Giangrande P, Poon MC, et al. Guidelines for the Management of Hemophilia. World Federation of Hemophilia, 2005. Available at: http://www/wfh.org/2/docs/Publications/Diagnosis-and-Treatment/ Guidelines-Mng-Hemophilia.pdf. Accessed on 26/09/2012.
9. National Hemophilia Foundation. Medical and Scientific Advisory Council. MASAC Recommendations concerning prophylaxis (regular administration of clotting factorconcentrate to prevent bleeding). Document 179. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid= 1007. Accessed on 26/09/2012.
10. Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
11. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77): 1-98.
12. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
13. van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
14. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on longterm outcome in patients with severe haemophilia. Blood 2002; 99: 2337-41.
15. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
16. Feldman BN, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
17. Xang MX, Blanchette VS, Pullenayegum E et al. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study Group. J Thromb Haemost 2011; 9: 1067-9.
18. Carcao M, Chambost H, Ljung R. Devising a best approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia 2010; 16 (Suppl. 2): 4-9.
19. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
20. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with longterm prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
21. Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
22. Pipe S. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010; 2010: 203-9.
23. Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-73.
24. Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23: 267-74.
25. den Uijl IEM, Biesma DH, Grobbee DE, Fischer K. Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal? Blood Transfus 2013; 11: 364-9.
26. den Uijl IE, Fischer K, Van Der Bom JG, et al. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15: 83-90.
27. Schu lman S, Eelde A, Holmström M, et al. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6: 1113-21.
28. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-53.